NCT04604652已完成2 期
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 24
- 主要终点
- Percent Change in Alkaline Phosphatase (ALP) at Week 12 Compared to Baseline
研究概览
简要总结
The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase at greater than or equal to1.5 times the upper limits of normal for the testing lab in spite of having been on adequate doses of standard therapy with UDCA (ursodeoxycholic acid) at 13-15 mg/kg for at least 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a clinical diagnosis of PBC as confirmed by patient history consistent with the American Association for the Study of Liver Diseases (AASLD) Practice Guideline confirmed by two of the following three criteria:
- •Biochemical evidence of cholestasis with elevation of ALP activity
- •Presence of antimitochondrial antibody (AMA)
- •Histopathologic evidence of non-suppurative cholangitis and destruction of small or medium-sized bile ducts if biopsy performed Note: historical AMA and liver biopsy data may be used but must be recorded in source documentation.
- •Has been taking a stable, adequate dose of at least (13-15 mg/kg/day) of UDCA for at least 6 months with a serum ALP of at least ≥1.5 × ULN at any time after being on UDCA for >6 months (historical value) and at Screening. If the historical ALP was obtained less than 6 months prior to study start as part of standard of care, the subject may be screened and a second ALP value should be obtained as part of screening, There must be at least a 4-week interval between the ALP values and the ALP values must be ≥1.5 × ULN
- •If the subject is taking cholestyramine or other bile acid sequestrant for pruritus, must be on a stable dose no more than once a day for at least 8 weeks prior to Baseline visit. Must be willing and able to take cholestyramine at least 2 hours before or after study medication
- •Females of child-bearing potential and males participating in the study must either agree to use at least two approved barrier methods of contraception or be completely abstinent from sexual intercourse, if this is their usual and preferred lifestyle, throughout the duration of the study and for three months after stopping study drug. Females who are postmenopausal must have appropriate documentation
- •Able to provide consent
排除标准
- •Uncontrolled concomitant autoimmune hepatitis (AIH). Subject should be on no more than 5 mg per day of prednisone (or equivalent dose for other corticosteroids) or no more than 150 mg per day of azathioprine at stable doses and serum ALT should be ≤ 5 × ULN. Enrollment of subjects with controlled AIH will be limited to a total of 5 subjects.
- •History of alcohol or substance abuse
- •Prior liver transplantation or currently listed for liver transplantation
- •History of chronic viral hepatitis, types B or C
- •Platelet count ≤150,000/mm3, albumin <3.0 g/dL, International Normalized Ratio (INR) >1.2, or a history of ascites, or encephalopathy, or history of variceal bleeding
- •Total bilirubin >1.3 × ULN unless subject has Gilbert Syndrome. If subject has increased total bilirubin due to Gilbert's Syndrome, then direct bilirubin should be <0.3 mg/dL.
- •Hemoglobin <10 g/dL for males or females
- •Serum TSH level <0.1 or >10 u/mL (subject may be re-screened if hyper- or hypothyroidism has been corrected)
- •Renal impairment with eGFR <60 ml/min (CKD stages 3, 4 or 5)
- •Human immunodeficiency virus (HIV)-1 or HIV-2 infection by history
- •Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- •History of malignancy within the past 2 years or ongoing malignancy other than basal cell carcinoma, or resected noninvasive cutaneous squamous cell carcinoma
- •Active, serious infections that require parenteral antibiotic or antifungal therapy within 30 days prior to Screening
- •Major surgical procedure within 30 days of Screening or prior solid organ transplantation
- •Females who are pregnant or breastfeeding
- •Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic agents, and immune-modulating agents (such as interleukins, interferons)
- •Diseases that may result in increased serum ALP activities from sources other than the biliary system (e.g., Paget's disease of bone, osteomalacia)
- •Allergy to the clinical trial material or its components
- •Having received any experimental medications within 28 days prior to Screening
- •Use of bezafibrate or fenofibrate within 28 days prior to first day of IP dosing
- •Use of obeticholic acid (OCA) within 28 days prior to first day of IP dosing
- •Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements
研究组 & 干预措施
Open-label
Experimental
HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.
干预措施: HTD1801 (BUDCA) (Drug)
结局指标
主要结局
Percent Change in Alkaline Phosphatase (ALP) at Week 12 Compared to Baseline
时间窗: Baseline to Week 12
To evaluate the effects of HTD1801 on serum ALP in adult subjects with PBC who have experienced an inadequate response to standard therapy. Inadequate response is defined as ALP ≥1.5 × upper limit of normal (ULN) despite having been on adequate doses of ursodeoxycholic acid (UDCA) for at least 6 months. A reduction in ALP represents an improvement.
次要结局
- Change in Total Bilirubin From Baseline to Week 12(Baseline to Week 12)
- Change in Serum Total Cholesterol From Baseline to Week 12(Baseline to Week 12)
- Change in Serum Gamma-glutamyl Transferase (GGT) From Baseline to Week 12(Baseline to Week 12)
- Change in Immunoglobulin M (IgM) From Baseline to Week 12(Baseline to Week 12)
- Change in Pruritus as Measured by Pruritus Visual Analog Score (VAS) From Baseline to Week 12(Baseline to Week 12.)
- Change in GLOBE Score Between Baseline and Week 12(Baseline to Week 12)
研究者
研究点 (24)
Loading locations...
相似试验
已完成
2 期
A Clinical Study to Evaluate CAD-1883 in Essential TremorEssential TremorNCT03688685Cadent Therapeutics25
已完成
2 期
Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric OxidePulmonary Arterial HypertensionNCT01092559Geno LLC10
招募中
1 期
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaMyelofibrosis Due to and Following Polycythemia VeraPost-essential Thrombocythemia MyelofibrosisMyelodysplastic SyndromesAnemia MyelofibrosisMyelofibrosisPrimary MyelofibrosisAnemiaNCT05320198Disc Medicine, Inc150
已完成
1 期
A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage TherapyHIV InfectionsNCT00002422Harbor Therapeutics42
已完成
1 期
A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected AdultsHIV/AIDSNCT03721510International AIDS Vaccine Initiative19